Open Label MM-111 in patients with HER2

• Research type

  Research Study

• Full title

  Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with Trastuzumab in Patients with HER2 Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

• IRAS ID

  122992

• Contact name

  David Watkins

• Contact email

  David.Watkins@rmh.nhs.uk

• Sponsor organisation

  Merrimack Pharmaceuticals Inc.

• Eudract number

  2012-003798-25

• ISRCTN Number

  N/A

• REC name

  London - South East Research Ethics Committee

• REC reference

  13/LO/0533

• Date of REC Opinion

  12 Jun 2013

• REC opinion

  Further Information Favourable Opinion